risperidone

Details

Generic Name:
risperidone
Project Status:
Suspended
Therapeutic Area:
Schizophrenia, adults
Manufacturer:
Teva Canada Innovation
Call for patient/clinician input open:
Brand Name:
TBC
Project Line:
Reimbursement Review
Project Number:
SR0811-000
Call for patient/clinician input closed:
NOC Status at Filing:
Pre NOC
Biosimilar:
No
Manufacturer Requested Reimbursement Criteria1:
For the treatment of schizophrenia in adults.
Submission Type:
Initial
Fee Schedule:
Schedule C
Indications:
​ For the treatment of schizophrenia in adults.
  1. The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of Canada's Drug Agency. Reimbursement criteria from Canada's Drug Agency will be documented in the final recommendation, if applicable.
Key Milestones2
Call for patient/clinician input open30-Aug-23
Call for patient/clinician input closed24-Oct-23
Clarification:

- No patient input submission received

Submission received13-Oct-23
Submission accepted27-Oct-23
Review initiated30-Oct-23
Draft CADTH review report(s) provided to sponsor for comment01-Feb-24
Deadline for sponsors comments12-Feb-24
Clarification:

- Submission temporarily suspended

CADTH review report(s) and responses to comments provided to sponsor-
Expert committee meeting (initial)-
Draft recommendation issued to sponsor-
Draft recommendation posted for stakeholder feedback-
End of feedback period-